Results 111 to 120 of about 15,628 (311)

Psychiatric effects of GLP‐1 receptor agonists: A systematic review of emerging evidence

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 50-59, January 2026.
Abstract This systematic review examines the current literature on glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs)‐associated psychiatric manifestations, including depression, suicidality, eating disorders, substance use disorders (SUD) and schizophrenia spectrum disorders.
Brianna Sa, Anthony Maristany, Ashwin Subramaniam, Ryan Guillen, Brooke Buonocore, Audrey Smith, Sean E. Oldak, Vanessa Padilla   +7 more
wiley   +1 more source

Drug-Induced Gynecomastia: Data Mining and Analysis of the FDA Adverse Event Reporting System Database

Clinical Epidemiology
Xiuli Yang,1 Xiaochun Zheng,1 Miaomiao Zhang,1,2 Jinlong Huang,1,2 Ping Huang,1,* Jiangfeng Wang1,3,* 1Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital ...
Yang X, Zheng X, Zhang M, Huang J, Huang P, Wang J   +5 more
doaj  

PDG43 SAFETY EVALUATION OF ZOLEDRONIC ACID AND DENOSUMAB USING FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) DATABASE 2012-2018 [PDF]

, 2019
Zizi Elsisi, Andrea Lin, J.J. Guo
openalex   +1 more source

Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System

International Journal of Dermatology, Volume 65, Issue 1, Page 108-118, January 2026.
ABSTRACT Background The United States Food and Drug Administration (FDA) approved oral finasteride for androgenetic alopecia. In 2022, approximately 2.6 million U.S. men used it for hair loss and prostate conditions. Post‐finasteride syndrome (PFS), proposed in 2012, involves persistent sexual and neuropsychiatric adverse events (AEs) after cessation ...
Aditya K. Gupta, Mesbah Talukder, Sharon A. Keene, Mary A. Bamimore   +3 more
wiley   +1 more source

Comparison of Infection Risks Between Various Inhaled and Intranasal Corticosteroids: A Pharmacovigilance Analysis Based on the FAERS Database

International Journal of COPD
Ying Lan,1 Die Hu,1 Shijing Huang,1 Qing Ma,1 Li Chen,2,3 Min Xu,1 Qin He1 1Department of Pharmacy, Affiliated Hospital of Southwest Jiaotong University, The Third People’s Hospital of Chengdu, Chengdu, Sichuan, 610031, People’s Republic of China ...
Lan Y, Hu D, Huang S, Ma Q, Chen L, Xu M, He Q   +6 more
doaj  

Broadening the Capture of Natural Products Mentioned in FAERS Using a Combined Approach

, 2023
Israel O. Dilan-Pantojas, Tanupat Boonchalermvichien, Sanya B. Taneja, Xiaotong Li, Maryann R. Chapin, Sandra Karcher, Richard D. Boyce   +6 more
openalex   +2 more sources

Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database

Frontiers in Pharmacology
Objective: This study aims to analyze adverse drug events (ADEs) associated with cenobamate from the FAERS database, covering the third quarter of 2020 to the second quarter of 2023.
Shihao Chen, Wenqiang Fang, Linqian Zhao, Huiqin Xu   +3 more
semanticscholar   +1 more source

Pharmacovigilance‐Based Identification and Mechanistic Exploration of Periodontitis‐Related Drugs

Journal of Clinical Periodontology, Volume 53, Issue 1, Page 117-126, January 2026.
ABSTRACT Background Periodontitis is a common chronic inflammatory disease. However, drug‐related risks and underlying molecular mechanisms remain underexplored from large real‐world data. Methods We first mined the US Food and Drug Administration Adverse Event Reporting System (FAERS) database to identify drugs disproportionately associated with ...
Wuda Huoshen, Junkai Xiong, Xunmi Ma, Heng Wang, Panyu Cheng, Xinyu Chen, Ge Shuai, Yi Chen, Xinyue Zhang, Chen Sun, Chunhui Li, Rui Shi   +11 more
wiley   +1 more source

Signal mining and analysis of adverse events of Brentuximab Vedotin base on FAERS and JADER databases.

PLoS ONE
ObjectivesBrentuximab Vedotin (BV) is a novel antibody-drug conjugate (ADC) approved for the treatment of classical Hodgkin's lymphoma and systemic anaplastic large cell lymphoma.
Feilong Tan, Yanhua Li, Hongying Xia, Wenjie Yin   +3 more
doaj   +1 more source

Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database

The Journal of Headache and Pain
Triptans selectively agoniste 5-Hydroxytryptamine(5-HT) receptors and are widely used in the treatment of migraine. Nevertheless, there is a dearth of comprehensive real-world clinical research on the safety of triptans.
Wen-Hui Liu, Hui-Min Hu, Chen Li, Qing Shi, Chun-Hua Liu, An-Xiang Liu, Yi-Fan Li, Yi Zhang, Peng Mao, Bi-Fa Fan   +9 more
semanticscholar   +1 more source